(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 August 2008 (28.08.2008)

PCT

(10) International Publication Number
WO 2008/103432 A1

(51) International Patent Classification:
C07K 16/24 (2006.01) *A61P 37/06* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2008/002333

(22) International Filing Date:
21 February 2008 (21.02.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/891,409 23 February 2007 (23.02.2007) US

(71) Applicant *(for all designated States except US)*: **SCHERING CORPORATION** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **PRESTA, Leonard, G.** [US/US]; 1900 Gough Street, Apt. 206, San Francisco, California 94109 (US). **BEYER, Brian, M.** [US/US]; 4401 Central Avenue, Matawan, New Jersey 07747 (US). **INGRAM, Richard, N.** [US/US]; 1454 Graymill Drive, Scotch Plains, New Jersey 07076 (US). **ORTH, Peter** [DE/US]; 100 West 93rd Street, Apartment 8H, New York, New York 10025 (US). **LIU, Yan-Hui** [US/US]; 125 Roland Road, Murray Hill, New Jersey 07974 (US).

(74) Agents: **BELLOMY, Gregory, R.** et al.; Schering-plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV,

[Continued on next page]

(54) Title: ENGINEERED ANTI-IL-23P19 ANTIBODIES

(57) Abstract: Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g., in treatment of inflammatory, autoimmune, and proliferative disorders.

```
                                        ---CDRH1--
m1A11   EVQLQQSGPELVKTGASVNISCKAS GYSFTAYYIQ WVKQSRGKSLEWIG
m11C1   HVQLQQSGPEVVRPGASVKLSCKAS GYIFSAYWMT WVKQRPGQGLEWIG
m5F5    QVQLQQSGAELARPGASVKLSCKAS GYTFTSYGIS WVKQRTGQDLEWIG
m21D1   QVQLQQSGLELVKPGSSLKISCKAS GYSFTSFFIH WLKQRPGQGLEWIG
m13B8   HVQLQQSGPELVRPGASVELSCKAS GYIFITYWMT WMKQRPGQGLEWIG
h13B8a  QVQLVQSGAEVKKPGASVKVSCKAS GYIFITYWMT WVRQAPGQGLEWMG
h13B8b  QVQLVQSGAEVKKPGASVKVSCKAS GYIFITYWMT WVRQAPGQGLEWMG
h13B8c  QVQLVQSGAEVKKPGASVKVSCKAS GYIFITYWMT WVRQAPGQGLEWMG

        ------CDRH2------
m1A11   YISCYNGATRYNQKFKG KATFTVDTSSRTAYMQFSSLTSEDSAVYFCAR
m11C1   QIFPVRGSADYNEIFEG KATLTVDTSSSTAYIQLSSLTSEDSAVYYCAR
m5F5    EIYPRSVNSYYNERFKG KATLTADKSSSTAYMELRSLTSEDSAVYFCAR
m21D1   WIFPGNHDVEYNEKFKG KATLTADTSSSTADMHLSSLTSEDSAVYFCAR
m13B8   QIFPASGSADYNEMFEG KATLTVDTSSNTAYMQLSSLTSEDSAVYFCAR
h13B8a  QIFPASGSADYNEMFEG RVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR
h13B8b  QIFPASGSADYNEKFEG RVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR
h13B8c  QIFPASGSADYAQKLQG RVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR

        -----CDRH3-----
m1A11   QGFYAMDY         WGQGTSVTVSS
m11C1   GGGGFAY          WGQGTLVTVSA
m5F5    GGNYYGRNYGDYFDY  WGQGTTLTVSS
m21D1   GGGNL--------PY  WGQGTLVTVSA
m13B8   GGGGFAY          WGQGTLVTVSA
h13B8a  GGGGFAY          WGQGTLVTVSS
h13B8b  GGGGFAY          WGQGTLVTVSS
h13B8c  GGGGFAY          WGQGTLVTVSS
```

Figure 1

WO 2008/103432 A1

SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*